{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T19:04:08Z","timestamp":1795201448287,"version":"4.10.3"},"reference-count":46,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current antithrombotic drugs, including widely used antiplatelet agents and anticoagulants, are associated with significant bleeding risk. Emerging experimental evidence suggests that the molecular and cellular mechanisms of hemostasis and thrombosis can be separated, thereby increasing the possibility of new antithrombotic therapeutic targets with reduced bleeding risk. We review new coagulation and platelet targets and highlight the interaction between integrin \u03b1M\u03b22 (Mac-1, CD11b\/CD18) on leukocytes and GPIb\u03b1 on platelets that seems to distinguish thrombosis from hemostasis.<\/jats:p>","DOI":"10.1182\/blood-2017-10-784074","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T18:18:11Z","timestamp":1519237091000},"page":"1899-1902","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["The search for new antithrombotic mechanisms and therapies that may spare hemostasis"],"prefix":"10.1182","volume":"131","author":[{"given":"Edward F.","family":"Plow","sequence":"first","affiliation":[{"name":"Cleveland Clinic Foundation; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunmei","family":"Wang","sequence":"additional","affiliation":[{"name":"Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Case Cardiovascular Research Institute, Case Western Reserve University School of Medicine, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I.","family":"Simon","sequence":"additional","affiliation":[{"name":"Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Case Cardiovascular Research Institute, Case Western Reserve University School of Medicine, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111907190964900_B1","first-page":"e21","article-title":"Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"119","author":"Lloyd-Jones","year":"2009","journal-title":"Circulation"},{"issue":"8","key":"2019111907190964900_B2","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"issue":"21","key":"2019111907190964900_B3","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"issue":"9696","key":"2019111907190964900_B4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","article-title":"Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial","volume":"374","author":"Mehran","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"2019111907190964900_B5","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1161\/01.RES.0000261936.85776.5f","article-title":"In vivo thrombus formation in murine models","volume":"100","author":"Sachs","year":"2007","journal-title":"Circ Res"},{"issue":"Suppl 2","key":"2019111907190964900_B6","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S0049-3848(16)30363-2","article-title":"Factor XI and factor XII as targets for new anticoagulants","volume":"141","author":"Weitz","year":"2016","journal-title":"Thromb Res"},{"key":"2019111907190964900_B7","first-page":"19","article-title":"Factors XI and XII as targets for new anticoagulants","volume":"4","author":"Weitz","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"2019111907190964900_B8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/j.1538-7836.2010.03893.x","article-title":"Hageman factor, platelets and polyphosphates: early history and recent connection","volume":"8","author":"Caen","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"2019111907190964900_B9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1538-7836.2009.03393.x","article-title":"Factor XI deficiency in animal models","volume":"7","author":"Renn\u00e9","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111907190964900_B10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1084\/jem.20052458","article-title":"Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis","volume":"203","author":"Kleinschnitz","year":"2006","journal-title":"J Exp Med"},{"issue":"3","key":"2019111907190964900_B11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111907190964900_B12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nm0302-247","article-title":"CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism","volume":"8","author":"Andr\u00e9","year":"2002","journal-title":"Nat Med"},{"issue":"21","key":"2019111907190964900_B13","doi-asserted-by":"crossref","first-page":"12367","DOI":"10.1073\/pnas.2032886100","article-title":"Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling","volume":"100","author":"Prasad","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111907190964900_B14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1172\/JCI22079","article-title":"Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy","volume":"115","author":"Angelillo-Scherrer","year":"2005","journal-title":"J Clin Invest"},{"issue":"8","key":"2019111907190964900_B15","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/j.1538-7836.2010.03935.x","article-title":"Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization","volume":"8","author":"Cosemans","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111907190964900_B16","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1182\/blood-2003-06-1781","article-title":"Signaling by ephrinB1 and Eph kinases in platelets promotes Rap1 activation, platelet adhesion, and aggregation via effector pathways that do not require phosphorylation of ephrinB1","volume":"103","author":"Pr\u00e9vost","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111907190964900_B17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.20030144","article-title":"A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo","volume":"198","author":"Hechler","year":"2003","journal-title":"J Exp Med"},{"issue":"5","key":"2019111907190964900_B18","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1172\/JCI70966","article-title":"Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis","volume":"124","author":"Wang","year":"2014","journal-title":"J Clin Invest"},{"issue":"12","key":"2019111907190964900_B19","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1172\/JCI26869","article-title":"Minding the gaps to promote thrombus growth and stability","volume":"115","author":"Brass","year":"2005","journal-title":"J Clin Invest"},{"issue":"7474","key":"2019111907190964900_B20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nature12613","article-title":"A directional switch of integrin signalling and a new anti-thrombotic strategy","volume":"503","author":"Shen","year":"2013","journal-title":"Nature"},{"issue":"52","key":"2019111907190964900_B21","doi-asserted-by":"crossref","first-page":"26598","DOI":"10.1074\/jbc.M116.747279","article-title":"G\u03b113 switch region 2 relieves talin autoinhibition to activate \u03b1IIb\u03b23 integrin","volume":"291","author":"Schiemer","year":"2016","journal-title":"J Biol Chem"},{"issue":"17","key":"2019111907190964900_B22","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/blood-2013-12-543363","article-title":"A talin mutant that impairs talin-integrin binding in platelets decelerates \u03b1IIb\u03b23 activation without pathological bleeding","volume":"123","author":"Stefanini","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111907190964900_B23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/ATVBAHA.114.303411","article-title":"Targeting integrin and integrin signaling in treating thrombosis","volume":"35","author":"Estevez","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2019111907190964900_B24","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/MOH.0000000000000070","article-title":"Shaping the platelet response to vascular injury","volume":"21","author":"Stalker","year":"2014","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"2019111907190964900_B25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/72162","article-title":"Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand","volume":"6","author":"Kawai","year":"2000","journal-title":"Nat Med"},{"issue":"23","key":"2019111907190964900_B26","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/CIRCULATIONAHA.107.724864","article-title":"First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers","volume":"116","author":"Gilbert","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"2019111907190964900_B27","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1160\/TH10-08-0520","article-title":"Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura","volume":"105","author":"Jilma-Stohlawetz","year":"2011","journal-title":"Thromb Haemost"},{"issue":"8","key":"2019111907190964900_B28","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.111.616649","article-title":"The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial","volume":"42","author":"Markus","year":"2011","journal-title":"Stroke"},{"issue":"9","key":"2019111907190964900_B29","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2016.12.022","article-title":"Neutrophil Counts and Initial Presentation of 12 Cardiovascular Diseases: A CALIBER Cohort Study","volume":"69","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"2019111907190964900_B30","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa035003","article-title":"Prognostic value of myeloperoxidase in patients with chest pain","volume":"349","author":"Brennan","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111907190964900_B31","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0735-1097(01)01485-1","article-title":"Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction","volume":"38","author":"Furman","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"2019111907190964900_B32","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/hc3801.095588","article-title":"Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction","volume":"104","author":"Michelson","year":"2001","journal-title":"Circulation"},{"key":"2019111907190964900_B33","doi-asserted-by":"crossref","first-page":"16124","DOI":"10.1038\/ncomms16124","article-title":"Corrigendum: Leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIb\u03b1","volume":"8","author":"Wang","year":"2017","journal-title":"Nat Commun"},{"issue":"2","key":"2019111907190964900_B34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1084\/jem.192.2.193","article-title":"Platelet glycoprotein Ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b\/CD18)","volume":"192","author":"Simon","year":"2000","journal-title":"J Exp Med"},{"issue":"7","key":"2019111907190964900_B35","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1084\/jem.20022181","article-title":"Targeting platelet-leukocyte interactions: identification of the integrin Mac-1 binding site for the platelet counter receptor glycoprotein Ibalpha","volume":"198","author":"Ehlers","year":"2003","journal-title":"J Exp Med"},{"issue":"19","key":"2019111907190964900_B36","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1161\/CIRCULATIONAHA.105.571315","article-title":"Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury","volume":"112","author":"Wang","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"2019111907190964900_B37","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1083\/jcb.120.4.1031","article-title":"The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b\/CD18) for four distinct adhesion ligands","volume":"120","author":"Diamond","year":"1993","journal-title":"J Cell Biol"},{"issue":"5","key":"2019111907190964900_B38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00062752-199704050-00005","article-title":"Structure and function of the glycoprotein Ib-IX-V complex","volume":"4","author":"L\u00f3pez","year":"1997","journal-title":"Curr Opin Hematol"},{"issue":"13","key":"2019111907190964900_B39","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1161\/CIRCULATIONAHA.109.873695","article-title":"Mac-1 (CD11b\/CD18) links inflammation and thrombosis after glomerular injury","volume":"120","author":"Hirahashi","year":"2009","journal-title":"Circulation"},{"issue":"9","key":"2019111907190964900_B40","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/CIRCRESAHA.111.256370","article-title":"Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis","volume":"110","author":"Langer","year":"2012","journal-title":"Circ Res"},{"issue":"13","key":"2019111907190964900_B41","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1161\/01.CIR.103.13.1718","article-title":"Inflammation and thrombosis: the clot thickens","volume":"103","author":"Libby","year":"2001","journal-title":"Circulation"},{"issue":"6","key":"2019111907190964900_B42","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood-2007-12-127183","article-title":"Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles","volume":"112","author":"Pluskota","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111907190964900_B43","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111907190964900_B44","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1084\/jem.160.6.1901","article-title":"Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis","volume":"160","author":"Springer","year":"1984","journal-title":"J Exp Med"},{"issue":"12","key":"2019111907190964900_B45","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.4049\/jimmunol.161.12.6463","article-title":"Impaired mast cell development and innate immunity in Mac-1 (CD11b\/CD18, CR3)-deficient mice","volume":"161","author":"Rosenkranz","year":"1998","journal-title":"J Immunol"},{"issue":"11","key":"2019111907190964900_B46","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/CIRCRESAHA.111.247684","article-title":"Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice","volume":"109","author":"Wolf","year":"2011","journal-title":"Circ Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/17\/1899\/1405788\/blood784074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/17\/1899\/1405788\/blood784074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:11:58Z","timestamp":1693548718000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/17\/1899\/36742\/The-search-for-new-antithrombotic-mechanisms-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,26]]},"references-count":46,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018,4,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-10-784074","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,26]]}}}